chapter 38/39: anti-neoplastic Flashcards
what is the clinical application of Gefitinib
non-small cell lung cancer
what are some adverse reactions seen with Gefitinib
interstitial lung disease, corneal erosion; rash, diarrhea
what is the mechanism of action of Gefitinib
reversible inhibitor of the EGFR (ErbB1) cytoplasmic tyrosine kinase domain; competes with ATP binding to the kinase domain
who has the most favorable response to Gefitinib
patients with bronchoalveolar cell carcinoma
what is the clinical application of Erlotinib
non-small cell lung cancer; carcinoma of pancreas
what are some adverse rxns seen with Erlotinib
MI, DVT, microangiopathic hemolytic anemia, elevated liver enzymes, stroke, conjunctivitis
what is the mechanism of action of Erlotinib
reversible inhibitor of EGFR (ErbB1) cytoplasmic tyrosine kinase domain
what is the clinical application of cetuximab
colorectal cancer; head and neck cancer
what are some adverse reactions seen with cetuximab
cardiac arrest, Pulmonary embolism, rash, diarrhea, hypomagnesemia, asthenia
what is the mechanism of action of cetuximab
monoclonal IgG antibody that binds to extracellular domain EGFR (ErbB1)
development of what is predictive of tumor response when cetuximab is used
development of rash
what is the clinical application of trastuzumab
breast cancer or metastatic gastric caner with HER2 over expression
what are some adverse reactions seen with trastuzumab
cardiotoxicity, nephrotic syndrome, leukopenia
what is the mechanism of action of trastuzumab
monoclonal IgG antibody against ErbB2 (HER2)
what is the clinical application of imatinib
CML expression the philadelphia chromosome; GI stroll tumor GIST expressing Kit (CD117); idiopathic hypereosinophilic syndrome
what are some adverse reactions see with imatinib
edema, myelosuppresion, nausea, muscle cramps, diarrhea, rash
what is the mechanism of action of sorafenib
inhibits both wild type and mutant B-RAF (RAS/MAP kinase pathway inhibitor)
what is the mechanism of action of rapamycin (sirolimus)
inhibits mTor but also blocks downstream targets of mTOR such as cyclin D1, c-MYC, BAD, and Hif-1
what is the mechanism of action of bortezomib
inhibits an active site N-terminal threonine residue within the 20S catalytic subunit of the proteasome
what is the clinical application of sorafenib
renal cell carcinoma, hepatocellular carcinoma
what is the clinical application of rapamycin (sirolimus)
prophylaxis for renal transplant rejection
what is the clinical application of bortezomib
multiple myeloma; mantle cell lymphoma
what are some adverse effects seen with sorafenib
CV disease, erythema multiform, hand-foot rash, elevated lipase and amylase levels; depressed blood cell counts; neuropathy
what are some adverse effects seen with rapamycin (sirolimus)
increased susceptibility to infection, lymphoma, malignancy; thrombotic microangiopathy; renal toxicity